Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15649531 | 0.86 | KDM4E (0.46) | NOD2NOD1TDP1KDM4EMAPT | |
| SCHEMBL8689838 | 0.86 | ALDH1A1 (0.54) | NOD2NOD1TDP1KDM4EMAPT | |
| SCHEMBL3091481 | 0.85 | NOD2 (0.46) | NOD2NOD1TDP1KDM4EMAPT | |
| SCHEMBL5621855 | 0.85 | NOD2 (0.46) | NOD2NOD1TDP1KDM4EMAPT | |
| SCHEMBL38652509 | 0.85 | NOD2 (0.46) | NOD2NOD1TDP1KDM4EMAPT | |
| SCHEMBL3954003 | 0.84 | L3MBTL1 (0.49) | NOD2NOD1KDM4ECCR2MEN1 | |
| SCHEMBL8688921 | 0.84 | KDM4E (0.52) | NOD2NOD1TDP1KDM4EMAPT | |
| SCHEMBL1392918 | 0.84 | NOD2 (0.64) | NOD2NOD1TDP1KDM4EMAPT | |
| SCHEMBL30585515 | 0.84 | NOD2 (0.64) | NOD2NOD1TDP1KDM4EMAPT | |
| SCHEMBL31424255 | 0.83 | MEN1 (0.44) | NOD2NOD1TDP1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8022213-B2 | 6'-Bromo-1-[(5-methoxy-3-methyl-1H-indol-2-yl)carbonyl]-1'H-spiro[piperidine-4,4'-quinolin]-2'(3'H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2089381-B1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-2102207-B1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2099799-B1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2102207-A1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| EP-2099799-A1 | SPIRO-PIPERIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| EP-2089381-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008068159-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068185-A1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
| US-7145009-B2 | Pirazino(aza)indole derivatives | VERNALIS RESEARCH LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20060160816-A1 | Pirazino(AZA) indole derivatives | VERNALIS RESEARCH LIMITED | 2006-07-20 | — | — | US | disclosed |
| US-6800627-B1 | CENTRAL NERVOUS SYSTEM, CARDIOVASCULAR AND GASTROINTESTINAL DISORDERS, DIABETES INSPIDUS, SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2004-10-05 | — | — | US | disclosed |
| US-20040092525-A1 | Pirazino(aza)indole derivatives | VERNALIS RESEARCH LIMITED | 2004-05-13 | — | — | US | disclosed |
| US-20040039200-A1 | Pirazino(AZA)indole derivatives | VERNALIS RESEARCH LIMITED | 2004-02-26 | — | — | US | disclosed |
| EP-1147110-B1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RES LTD (GB) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092525-A1 | Pirazino(aza)indole derivatives | PIR, GPR119, INMT | NOD2 2238/4885NOD1 418/4885TDP1 1746/4885 |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | NOD2 1529/4885NOD1 1159/4885TDP1 4041/4885 |
| US-20060160816-A1 | Pirazino(AZA) indole derivatives | PIR, GPR119, INMT | NOD2 2184/4885NOD1 581/4885TDP1 2076/4885 |
| US-20080139618-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | NOD2 1617/4885NOD1 1218/4885TDP1 3004/4885 |
| US-20040039200-A1 | Pirazino(AZA)indole derivatives | PIR, GPR119, INMT | NOD2 2238/4885NOD1 418/4885TDP1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.